Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 14-03-2024 | Micafungin | Original Article

Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans

Authors: Alina Nussbaumer-Pröll, Peter Matzneller, Sabine Eberl, Markus Zeitlinger

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2024

Abstract

Purpose

This study investigates how surfactants affect the in-vitro anti-infective efficacy of micafungin, caspofungin, anidulafungin, and amphotericin B in treating pulmonary mycoses.

Methods

MIC values for antifungal agents were determined against Candida krusei (now Pichia kudriavzevii) ATCC 6258, Candida albicans ATCC 90028, and 18 clinical isolates using the broth microdilution method in RPMI medium, following EUCAST recommendations. MIC assays included testing with and without Curosurf® surfactant at 1 mg/mL for C. krusei ATCC 6258 and all C. krusei isolates. Subsequent Time-kill studies in Sabouraud broth involved testing both C. albicans ATCC 90028 and C. krusei ATCC 6258 strains at concentrations equal their respective MIC values, with and without surfactant, using all four antifungals. CFU/mL were assessed at multiple time points up to 24 h. TKCs with different surfactant concentrations for C. krusei ATCC 6258 and mini-TKCs at various concentrations relative to the MIC of C. krusei isolates and the reference strain were conducted with micafungin, anidulafungin, and caspofungin.

Results

MIC results showed that 1 µg/mL surfactant reduced killing of micafungin and anidulafungin against C. krusei, while caspofungin was unaffected. Amphotericin B's MIC decreased by half. TKCs demonstrated significant effects of surfactant on micafungin and anidulafungin against C. krusei, with complete abolition of anidulafungin's activity against C. albicans.

Conclusion

This in-vitro study highlights the concentration-dependent inhibitory effect of surfactant on antifungal activity against C. krusei and, to some extent, C. albicans, necessitating further clinical validation for invasive lung mycoses treatment.

Griese M (1999) Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 13(6):1455–1476CrossRefPubMed

van’t Veen A et al (1996) Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br J Pharmacol 118(3):593–8CrossRef

Kharasch VS et al (1991) Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 144(4):909–913CrossRefPubMed

van’t Veen A et al (1999) Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle. Br J Pharmacol 126(5):1091–6CrossRef

Schwameis R, Erdogan-Yildirim Z, Manafi M, Zeitlinger MA, Strommer S, Sauermann R (2013) Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother 57(10):5151–4. https://doi.org/10.1128/AAC.00778-13CrossRefPubMedPubMedCentral

Nussbaumer-Pröll A, Eberl S, Belley A, Knechtle P, Huband MD, Huynh HK, Zeitlinger M (2023) Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae. J Antibiot (Tokyo) 76(3):183–189. https://doi.org/10.1038/s41429-022-00592-wCrossRefPubMed

Silverman JA et al (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191(12):2149–2152CrossRefPubMed

Rauwolf KK, Hoertnagl C, Lass-Floerl C, Groll AH (2022) Interaction in vitro of pulmonary surfactant with antifungal agents used for treatment and prevention of invasive aspergillosis. J Antimicrob Chemother 77(3):695–698. https://doi.org/10.1093/jac/dkab422CrossRefPubMed

Kousha M, Tadi R, Soubani AO (2011) Pulmonary aspergillosis: a clinical review. Eur Respir Rev 20(121):156–174. https://doi.org/10.1183/09059180.00001011CrossRefPubMedPubMedCentral

10.

Smith JA, Kauffman CA (2012) Pulmonary fungal infections. Respirology 17(6):913–926CrossRefPubMed

11.

Lepak AJ, Andes DR (2011) Antifungal PK/PD considerations in fungal pulmonary infections. Semin Respir Crit Care Med 32(6):783–794. https://doi.org/10.1055/s-0031-1295726CrossRefPubMed

12.

Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, Alfaro RM, Schaufele RL, Sein T, Bacher J, Walsh TJ (2006) Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 50(10):3418–3423. https://doi.org/10.1128/AAC.00241-06CrossRefPubMedPubMedCentral

13.

Jahn B, Rampp A, Dick C, Jahn A, Palmer M, Bhakdi S (1998) Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level. Antimicrob Agents Chemother 42(10):2569–2575. https://doi.org/10.1128/AAC.42.10.2569CrossRefPubMedPubMedCentral

14.

Roilides E, Lyman CA, Filioti J, Akpogheneta O, Sein T, Lamaignere CG, Petraitiene R, Walsh TJ (2002) Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 46(6):1974–1976. https://doi.org/10.1128/AAC.46.6.1974-1976.2002CrossRefPubMedPubMedCentral

15.

Chiller T, Farrokhshad K, Brummer E, Stevens DA (2001) The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 39(2):99–103. https://doi.org/10.1016/s0732-8893(00)00236-4CrossRefPubMed

16.

Choi JH, Brummer E, Stevens DA (2004) Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect 6(4):383–389. https://doi.org/10.1016/j.micinf.2003.12.010CrossRefPubMed

17.

Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC (2011) Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 55(12):5732–9. https://doi.org/10.1128/AAC.00637-11CrossRefPubMedPubMedCentral

18.

Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Sheppard DC (2013) Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. J Infect Dis 208(10):1717–28. https://doi.org/10.1093/infdis/jit358CrossRefPubMedPubMedCentral

19.

Gil-Alonso S, Jauregizar N, Cantón E, Eraso E, Quindós G (2015) Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves. Diagn Microbiol Infect Dis 82(1):57–61. https://doi.org/10.1016/j.diagmicrobio.2015.01.010CrossRefPubMed

20.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62(4):e1–e50. https://doi.org/10.1093/cid/civ933CrossRefPubMed

21.

Erami M, Raiesi O, Momen-Heravi M, Getso MI, Fakhrehi M, Mehri N, Yarahmadi M, Amiri S, Raissi V, Hashemi SJ (2022) Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia. Microb Pathog 166:105520. https://doi.org/10.1016/j.micpath.2022.105520CrossRefPubMedPubMedCentral

Title: Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans
Authors: Alina Nussbaumer-Pröll
Peter Matzneller
Sabine Eberl
Markus Zeitlinger
Publication date: 14-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Micafungin
Caspofungin
Amphotericin B
Candida Albicans
Candida Balanitis
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2024
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-024-04799-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Evaluation of CLINITEST® Rapid Covid-19 + Influenza antigen test in a cohort of symptomatic patients in an emergency department

Molecular monitoring of viral infections in immunocompromised patients in a large university hospital in Italy: reflections after thirteen years of real-life activity

Unmasking Bartonella henselae infection in the shadows of long COVID thanks to clinical metagenomics

In vitro susceptibility of Neisseria gonorrhoeae to netilmicin and etimicin in comparison to gentamicin and other aminoglycosides

A decade of neonatal sepsis in Stockholm, Sweden: Gram-positive pathogens were four times as common as Gram-negatives

Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials